| Discover Sources And More: BSEM Website. BSEM Presentation. -----
5 Explosive Potential Catalysts Put (BSEM) On Radar Watch
#1. BSEM Has A Fairly Low Float (Volatility Potential Could Be Explosive).
With a float of roughly 6.82Mn shares, according to the OTC Markets' website, volatility potential could pop up in a flash.
#2. A $25.50 Analyst Target Spells Triple-Digit Potential Upside For BSEM.
Brad Sorensen of Zacks Small-Cap Research has pegged a $25.50 target on BSEM.
From its closing valuation on Wednesday, this target suggests BSEM may have a potential 500+% upside.
#3. An Innovative Product Line Advances Veteran Wound Care Through American Amnion Launch.
BioStem Technologies® introduced its new American Amnion™ product line at the 2025 Desert Foot Conference, marking a major advancement in wound care for veterans.
Using proprietary BioRetain® technology, the products preserve the natural structure of human amnion and chorion membranes for optimal healing.
Clinical studies show nearly double the wound closure rates compared to standard care and improved cost-effectiveness.
The Company CEO, Jason Matuszewski, emphasized BioStem’s commitment to improving veteran health and community support through initiatives like sponsoring the Florida Panthers’ Heroes Among Us program.
#4. BioStem Technologies Strengthens Access Through Expanded Medicaid Coverage Nationwide.
BioStem Technologies achieved a major step forward as Florida Medicaid added VENDAJE® and VENDAJE AC® to its list of covered skin substitutes.
This inclusion extends BioStem’s advanced wound care access to thirteen Medicaid programs nationwide, reinforcing the company’s mission of delivering high-quality, evidence-based healing solutions.
CEO Jason Matuszewski believes that Florida’s large Medicaid market will greatly expand BioStem’s patient reach.
The move validates the clinical and economic value of its technology and positions Medicaid expansion as a key long-term growth driver in the $11Bn U.S. wound care market.
#5. BioStem Technologies Achieves Breakthrough Success With BioREtain® Clinical Trial Results.
BioStem Technologies announced strong top-line results showing its BioREtain® allograft significantly outperformed standard care in treating diabetic foot ulcers.
Published in the International Journal of Tissue Repair, the randomized trial revealed a 53% healing rate for BioREtain® versus 31% for standard treatment, nearly doubling the probability of lasting wound closure.
Conducted under FDA-rigorous standards with hard-to-heal patients, the study validates BioREtain’s superior performance.
CEO Jason Matuszewski emphasized the findings strengthen BioStem’s clinical credibility, encouraging broader adoption and commercial growth in advanced wound care solutions. -----
Coverage is officially underway on BioStem Technologies, Inc. (BSEM)
Updates will be coming your way shortly. Keep your eyes peeled.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 01/21/2026 and ending on 01/22/2026 to publicly disseminate information about (BSEM:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid six thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid thirteen thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (BSEM:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/bsem-vbkxr/#details | 
0 التعليقات:
إرسال تعليق